Amorphous solid dispersion development
Amorphous solid dispersions enhance oral bioavailability by generating drug concentrations far above the solubility of the crystalline form.
Our expertise lies in maximising that supersaturation: we design formulations that stabilise the amorphous state on shelf and inhibit crystallisation after dissolution.
Our expertise lies in maximising that supersaturation: we design formulations that stabilise the amorphous state on shelf and inhibit crystallisation after dissolution.
Sustained supersaturation
Polymer selection guided by dissolution and precipitation testing, so the amorphous advantage lasts long enough to matter.
Material-sparing screening
Small-scale assays to evaluate multiple formulations from limited API.
Rational formulation design
Choices based on your compound's physicochemical properties, not trial-and-error.